BioTech Startups Want to Revive Failed Medicines to Create New Lifesaving Treatments

Some Cancer-fighting compounds for kids gather dust on Big Pharma’s lab shelves. Children’s Tumor Foundation President Annette Bakker, Ph.D., won’t stand for that. She shared her efforts to rescue these assets with I Don’t Care’s Kevin Stevenson.

In her fight to end neurofibromatosis, an incurable condition that causes tumors to grow on the brain and spinal cord, Bakker is pioneering game-changing ideas in disease research.

Through Bakker’s experience in the pharmaceutical and biochemistry industries, she learned how separate the two ecosystems were. “The motivations that drive academic researchers are publications,” Bakker said. “The motivations that drive pharmaceutical companies is to develop those drugs, but in the meantime also to fuel the development of new drugs they need to patent. So, they need to keep the stuff secret. The very different systems these two worlds are living in make it difficult to translate discoveries into better treatments for patients.”

Bridging the gap in science politics to ensure discoveries lead to better treatments is the space where Bakker lives. “It’s about bringing the models to the drugs,” Bakker said. “It’s about bringing the different stakeholders together and creating that ecosystem.”

What led Bakker from her background in biochemistry to the pharmaceutical world was the desire to take great discoveries and make sure they were getting used. And what ultimately led her to The Children’s Tumor Foundation (CTF) was to be a part of the solution in bridging the gaps, cutting through the red tape, and connecting the right people to make real change. “My philosophy is always, ‘move the foot,’ Bakker said. “Don’t blame anyone; incentivize them to change their behavior and feel good about it.”

More Like This Story:

From an Idea to Billion Dollar Company: How a Doctor Lobbied DC for HSAs

Does the Insurance Model of the Future Exclude A Traditional Health Insurance Carrier

Follow us on social media for the latest updates in B2B!

Image

Latest

reviews
The New Freight Standard: Why Verified Trucking Reviews Matter in Modern Supply Chains
September 11, 2025

For decades, the freight industry has leaned heavily on compliance data and opaque reputation systems, leaving carriers, brokers, and shippers with little visibility into actual service quality. Reviews often sat behind paywalls, skewed negative, or lacked validation altogether, making it difficult to separate reliable partners from unreliable ones. Today, the vast majority of trucking remains…

Read More
Culture
Culture as a Growth Engine: How People-First Values Create Long-Term Success in a Tech-Driven Age
September 10, 2025

Companies everywhere are racing to integrate AI and automation into their operations—but what happens when technology threatens the very people who power the business? A recent Mercer study found that while executives see AI as a major driver of productivity, many admit their organizations are struggling to keep their workforce prepared for the pace of…

Read More
Nonprofits
The Ethics of Innovation: How Nonprofits Can Harness AI Without Losing Their Mission
September 10, 2025

Artificial intelligence is reshaping industries at a staggering pace, with nonprofit leaders now facing the same challenges and opportunities as their corporate counterparts. According to a Harvard Business Review study of 100 companies deploying generative AI, four strategic archetypes are emerging—ranging from bold innovators to disciplined integrators. For nonprofits, the stakes are even higher: harnessing…

Read More
Why Reliability Is the Real Currency in EV Charging
September 10, 2025

How trust, measured in uptime and delivered through engineering excellence, drives the future of electric transportation   The 3 AM Test: When Reliability Reveals Its True Value Picture this: It’s 3 AM in Houston, and an emergency towing fleet needs to dispatch vehicles immediately. The trucks are electric, the call is urgent, and there’s…

Read More